FROM Katie Thomas
Can politics cure the high cost of drugs? EpiPens are the poster child for vast increases in the price of familiar medications. Many people carry them for emergency treatment of allergic reactions that can be life threatening. So, when the Mylan Company raised the price of two EpiPens from $100 $614 it made big news. Turns out, it's the tip of the iceberg. Drug prices are on the rise and desperately ill people are often those hit by bills they never expected. Other countries have established price controls for life-or-death medications, but America's system is so complex it defies understanding. Drug and insurance companies, hospitals and doctors engage in secret negotiations, while various middlemen get cuts of the action. And, who's paying for those expensive ads on TV? Patients. Are the presidential campaigns offering any realistic solutions?
Shoddy Practices at Big Drug Makers So-called "compounding pharmacies" regulated by the states have been taking heat since the recent outbreak of meningitis. Today's New York Times reports that one-third of the drug manufacturing industry overseen by the Food and Drug Administration is off line because of "quality issues." Katie Thomas covers the business of healthcare for the New York Times .
The US gets deeper into Middle East wars. What's the endgame? President Trump welcomed Egypt's President Abdul Fattah al-Sisi to the White House today… just one of the changes in America's approach to the Middle East since Barack Obama left office. We hear about that and the escalation of warfare as well as civilian casualties.
White House flip flops: NATO, Syria and China In less than 100 days, President Trump has contradicted himself on a host of foreign policy issues — Syria, NATO, China and Vladimir Putin’s Russia. Is it a strength — or a weakness — for the United States when the world of power politics never knows what to expect?